Clinical Trial Update: Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study [Phase 2]

View source ↗

Summary

This Phase 2 INTERACT trial evaluated adding fulvestrant to aromatase inhibitor therapy for HR-positive metastatic breast cancer with an ESR1 activating mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor therapy (unspecified) (aromatase inhibitor)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-12-27